The phase 2 result
Mean loss of 18.7% at 46 weeks at the max 6 mg weekly dose vs 2.0% placebo, per final data presented at EASD 2024. The curve didn't plateau by the end of the study, suggesting additional loss capacity with prolonged treatment.
The mechanism
Survodutide is a dual GLP-1 + glucagon agonist (no GIP, unlike tirzepatide). The glucagon component adds energy expenditure and hepatic fat oxidation — particularly attractive for the MASH/NASH subgroup. Boehringer launched a parallel phase 3 MASH program called LIVER, with data expected in 2026.
The Boehringer + Zealand Pharma alliance
Zealand Pharma, a Danish biotech, discovered the molecule and licensed global rights to Boehringer in 2014. It collects tiered royalties (up to 12% on peak sales) plus milestones up to €392 million. Zealand shares are up +180% in 2024 on survodutide progress.
Why Europe wants to win this one
Novo Nordisk (Wegovy/Ozempic) is Danish. But the IP of Wegovy's core components was designed 25+ years ago. Survodutide is the first 'made in Europe' molecule with phase 2 efficacy comparable to tirzepatide. Boehringer plans launch in 2027 — the same year as retatrutide.